UK government guidance on Alzheimer's drugs postponed.
O'Neill
Michael F
MF
D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000077265:Donepezil; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D035082:Federal Government; D005702:Galantamine / Q000627:therapeutic use; D033161:Government Regulation; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008559:Memantine / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use; D048448:Phenylcarbamates / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D000068836:Rivastigmine; D006113:United Kingdom
D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D007189:Indans; D018697:Nootropic Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine; D008559:Memantine